日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

PD-1-Cis IL-2R Agonism Determines the Predicted Pharmacological Dose Range for the Immunocytokine Eciskafusp Alfa (PD1-IL2v)

PD-1-Cis IL-2R激动作用决定了免疫细胞因子Eciskafusp Alfa (PD1-IL2v)的预测药理剂量范围

Hutchinson, Lucy G; Lewin, Thomas D; Lauener, Laura; Martin-Facklam, Meret; Muecke, Merlind; Teichgraeber, Volker; Codarri Deak, Laura

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

CEA-CD3双特异性抗体cibisatamab联合或不联合atezolizumab治疗CEA阳性实体瘤患者:两项多中心I期试验的结果

Segal, Neil H; Melero, Ignacio; Moreno, Victor; Steeghs, Neeltje; Marabelle, Aurelien; Rohrberg, Kristoffer; Rodriguez-Ruiz, Maria E; Eder, Joseph P; Eng, Cathy; Manji, Gulam A; Waterkamp, Daniel; Leutgeb, Barbara; Bouseida, Said; Flinn, Nick; Das Thakur, Meghna; Elze, Markus C; Koeppen, Hartmut; Jamois, Candice; Martin-Facklam, Meret; Lieu, Christopher H; Calvo, Emiliano; Paz-Ares, Luis; Tabernero, Josep; Argilés, Guillem

Enhancing the Functionality of Immunoisolated Human SC-βeta Cell Clusters through Prior Resizing.

通过预先调整大小来增强免疫分离的人类 SC-β 细胞簇的功能

Bochenek Matthew A, Walters Ben, Zhang Jingping, Fenton Owen S, Facklam Amanda, Kroneková Zuzana, Pelach Michal, Engquist Elise N, Leite Nayara C, Morgart Alex, Lacík Igor, Langer Robert, Anderson Daniel G

Characterization of anti-drug antibody responses to the T-cell engaging bispecific antibody cibisatamab to understand the impact on exposure

对T细胞结合双特异性抗体cibisatamab的抗药抗体反应进行表征,以了解其对药物暴露的影响

Lotz, Gregor P; Lutz, Achim; Martin-Facklam, Meret; Hansbauer, Andre; Schick, Eginhard; Moessner, Ekkehard; Antony, Michael; Stuchly, Thomas; Viert, Maria; Hosse, Ralf J; Freimoser-Grundschober, Anne; Klein, Christian; Schäfer, Martin; Ritter, Mirko; Stubenrauch, Kay-Gunnar

Partially Oxidized Alginate as a Biodegradable Carrier for Glucose-Responsive Insulin Delivery and Islet Cell Replacement Therapy

部分氧化藻酸盐作为可生物降解的载体,用于葡萄糖响应性胰岛素递送和胰岛细胞替代疗法

Volpatti, Lisa R; Bochenek, Matthew A; Facklam, Amanda L; Burns, Delaney M; MacIsaac, Corina; Morgart, Alexander; Walters, Benjamin; Langer, Robert; Anderson, Daniel G

A wireless, battery-free device enables oxygen generation and immune protection of therapeutic xenotransplants in vivo

一种无线、无电池装置能够在体内为治疗性异种移植提供氧气生成和免疫保护。

Krishnan, Siddharth R; Liu, Claudia; Bochenek, Matthew A; Bose, Suman; Khatib, Nima; Walters, Ben; O'Keeffe, Laura; Facklam, Amanda; Langer, Robert; Anderson, Daniel G

Promoting Health Literacy Among Adult ELLs Virtually During COVID-19

在新冠疫情期间通过线上方式提升成年英语学习者的健康素养

Shashikiran, Sannidhi; Mendoza, Janessa M; Facklam, Amy; Riley, Joan B

A retrievable implant for the long-term encapsulation and survival of therapeutic xenogeneic cells

一种可回收植入物,用于长期封装和维持治疗性异种细胞的存活。

Suman Bose ,Lisa R Volpatti # ,Devina Thiono # ,Volkan Yesilyurt ,Collin McGladrigan ,Yaoyu Tang ,Amanda Facklam ,Amy Wang ,Siddharth Jhunjhunwala ,Omid Veiseh ,Jennifer Hollister-Lock ,Chandrabali Bhattacharya ,Gordon C Weir ,Dale L Greiner ,Robert Langer ,Daniel G Anderson

The Association of Tacrolimus Formulation Switching with Trough Concentration Variability: A Retrospective Cohort Study of Tacrolimus Use Post-Kidney Transplantation Based on National Drug Code (NDC) Numbers

他克莫司制剂转换与谷浓度变异性的关联:基于国家药品代码(NDC)编号的肾移植后他克莫司使用回顾性队列研究

Schwartz, Jason J; Lee, Edward; Butler, Ashley P; Facklam, David P; Franks, Billy; Spalding, James R; Vassilakis, Maria E; Thal, Gary D; Irish, William D

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial

PRX002/RG7935(一种抗α-突触核蛋白单克隆抗体)多次递增剂量治疗帕金森病患者的安全性和耐受性:一项随机临床试验

Jankovic, Joseph; Goodman, Ira; Safirstein, Beth; Marmon, Tonya K; Schenk, Dale B; Koller, Martin; Zago, Wagner; Ness, Daniel K; Griffith, Sue G; Grundman, Michael; Soto, Jay; Ostrowitzki, Susanne; Boess, Frank G; Martin-Facklam, Meret; Quinn, Joseph F; Isaacson, Stuart H; Omidvar, Omid; Ellenbogen, Aaron; Kinney, Gene G